Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients (Q36299985)

13 August 2017

1 reference

title

Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients (English)

1 reference

13 August 2017

1 reference

3

Cesare Gridelli

1 reference

13 August 2017

Antonio Rossi

1

1 reference

13 August 2017

Paolo Maione

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Expert Opinion on Drug Safety

13 August 2017

published in

1 reference

13 August 2017

volume

4

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

1051-1067

1 reference

Estimating the world cancer burden: Globocan 2000.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Lung cancer in Europe in 2000: epidemiology, prevention, and early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

21 January 2018

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Geriatric oncology: challenges for the new century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Geriatric Pharmacology: Basic and Clinical Considerations*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Cancer in the frail patient. A coming epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Management of the frail person with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Cancer in the elderly: why so badly treated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Prescribing anti-cancer drugs in elderly cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Psychotropic drug metabolism in the cancer patient: clinical aspects of management of potential drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Cancer and aging. An evolving panorama

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Particular aspects of platinum compounds used at present in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Use of Cisplatin for Elderly Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

Lung cancer mortality in European regions (1955-1997)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1051

10.1517/14740338.4.6.1051

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference